All In Biotech

Investigational drug · Phase 2

MK-3120

Also called: SKB410

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

4

Any phase or sponsor naming "MK-3120"

First trial start

2022

Nov 16, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MK-3120", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bladder Cancer
  • Advanced Solid Tumors
  • Malignant Neoplasm
  • Urinary Bladder Neoplasms
  • Urothelial Carcinoma

Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "MK-3120" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Bladder Cancer

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • CetrelimabJNJ-63723283Phase 38 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

  • VisugromabCTL-002, Visugromab RDEPhase 36 trials

    CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma

  • TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer

  • Cretostimogene GrenadenorepvecCG0070Phase 34 trials

    CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer

  • BrigimadlinBI 907828Phase 33 trials

    Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.